“Some times I get up and can’t believe how considerably we’ve come,” claimed Dr. Doblin, 67, who now oversees the Multidisciplinary Association for Psychedelic Research, a multimillion dollar analysis and advocacy empire that employs 130 neuroscientists, pharmacologists and regulatory experts working to put the groundwork for the approachin